Literature DB >> 8329391

Determination of the reduction-oxidation potential of the thioredoxin-like domains of protein disulfide-isomerase from the equilibrium with glutathione and thioredoxin.

J Lundström1, A Holmgren.   

Abstract

Protein disulfide-isomerase (PDI) contains two thioredoxin-like domains with the active-site sequence: Cys-Gly-His-Cys. Reduction of the two active-site disulfides in PDI by NADPH and bovine thioredoxin reductase was not reversible by addition of excess NADP+, consistent with a redox potential (E0') above -200 mV. Redox states of PDI and a mutated Escherichia coli thioredoxin, P34H Trx, were determined by quantitative analysis of cysteine residues by alkylation in equilibrium mixtures of oxidized and reduced forms of the two proteins. From the known E0' of P34H Trx (-235 mV), an E0' value of -190 +/- 10 mV was calculated for PDI. Similarly, with defined redox buffers of glutathione, the redox-active dithiols in PDI were shown to have an equilibrium constant of 3 mM (E0' = -175 +/- 15 mV). The results showed that PDI has a high redox potential and therefore is a good oxidant of nascent protein thiols. Direct transfer of reducing equivalents from PDI to NADP+ via thioredoxin reductase during protein disulfide formation seems unlikely due to the unfavorable equilibrium. The thioredoxin domains in PDI have a widely different redox potential compared with that of thioredoxin. A Pro to His exchange in the active site contributes to half of the change; the other half remains to be identified in the structure of PDI.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8329391     DOI: 10.1021/bi00077a018

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  58 in total

1.  The CXXC motif at the N terminus of an alpha-helical peptide.

Authors:  Teuku M Iqbalsyah; Efrosini Moutevelis; Jim Warwicker; Neil Errington; Andrew J Doig
Journal:  Protein Sci       Date:  2006-08       Impact factor: 6.725

2.  The CXXC motif: imperatives for the formation of native disulfide bonds in the cell.

Authors:  P T Chivers; M C Laboissière; R T Raines
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

3.  Reduced monomeric CD4 is the preferred receptor for HIV.

Authors:  Lisa J Matthias; Iman Azimi; Catherine A Tabrett; Philip J Hogg
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

Review 4.  Vascular thiol isomerases.

Authors:  Robert Flaumenhaft; Bruce Furie
Journal:  Blood       Date:  2016-06-29       Impact factor: 22.113

5.  Endoplasmic reticulum-resident protein 57 (ERp57) oxidatively inactivates human transglutaminase 2.

Authors:  Michael C Yi; Arek V Melkonian; James A Ousey; Chaitan Khosla
Journal:  J Biol Chem       Date:  2018-01-05       Impact factor: 5.157

6.  An additional function of the rough endoplasmic reticulum protein complex prolyl 3-hydroxylase 1·cartilage-associated protein·cyclophilin B: the CXXXC motif reveals disulfide isomerase activity in vitro.

Authors:  Yoshihiro Ishikawa; Hans Peter Bächinger
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

7.  Disulfide reduction in CD4 domain 1 or 2 is essential for interaction with HIV glycoprotein 120 (gp120), which impairs thioredoxin-driven CD4 dimerization.

Authors:  Nichole Cerutti; Mark Killick; Vinesh Jugnarain; Maria Papathanasopoulos; Alexio Capovilla
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

Review 8.  Regulatory role of thiol isomerases in thrombus formation.

Authors:  Anish Sharda; Bruce Furie
Journal:  Expert Rev Hematol       Date:  2018-03-28       Impact factor: 2.929

9.  The CXC motif: a functional mimic of protein disulfide isomerase.

Authors:  Kenneth J Woycechowsky; Ronald T Raines
Journal:  Biochemistry       Date:  2003-05-13       Impact factor: 3.162

Review 10.  Oxidative protein folding: from thiol-disulfide exchange reactions to the redox poise of the endoplasmic reticulum.

Authors:  Devin A Hudson; Shawn A Gannon; Colin Thorpe
Journal:  Free Radic Biol Med       Date:  2014-08-01       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.